Search

Your search keyword '"Habr Gama A"' showing total 1,368 results
Start Over Author "Habr Gama A"
1,368 results on '"Habr Gama A"'

1. Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer

Author

Fernandez, Laura M., São Julião, Guilherme P., Santacruz, Carlos Cerdan, Renehan, Andrew G., Cano-Valderrama, Oscar, Beets, Geerard L., Azevedo, Jose, Lorente, Blas F., Rancaño, Rocío S., Biondo, Sebastiano, Espin-Basany, Eloy, Vailati, Bruna B., Nilsson, Per J., Martling, Anna, Van De Velde, Cornelis J.H., Parvaiz, Amjad, Habr-Gama, Angelita, Perez, Rodrigo O., Antona, Francisco Blanco, Martín, Elena Yagüe, Tébar, Jesús Cifuentes, Calvo, Alberto Parajó, Quintana, Natalia Uribe, Alonso, Mauricio García, Cotoré, Jesús Paredes, Riesco, Ana Benítez, Cánovas, Noelia Ibañez, Sanchez, Camen Martinez, Ribe i Serrat, Didac, Ais, Guillermo, Jiménez Toscano, Marta, Climent, Antonio, Reig Pérez, Monica, Sierra Grañón, José Enrique, Mateo, Janire, Biondo, Sebastiano, Saldaña, Ana Gálvez, Laso, Carlos Álvarez, Allende, Ignacio Aguirre, Álvarez, Daniel Huerga, Coll, Ramón Farrés, Sánchez Bautista, Wilson M., Torres Sánchez, Maria Teresa, Dujovne, Paula, Camps, Ignasi, Cuadrado, Marta, Díaz, Olga Maseda, Sánchez, Nieves, de la Vega Olías, Maria del Coral, Basan, Eloy Espin, Carre, Miquel Kraft, Aghili, Mahdi, Arnold, Marion, Asoglu, Oktar, Bujko, Krzysztof, Caiado, André, Carvalho, Carlos, Chautems, Ronald, Coco, Claudio, Chiloiro, Giuditta, Cunningham, Chris, Custers, Petra, Haak, Hester, DʼHoore, André, Dimofte, Gabriel, Ding, Peirong, Duff, S., Felicio, Natalia, Figueiredo, Nuno, Gaertner, Wolfgang, Gérard, Jean-Pierre, Gama-Rodrigues, Joaquim, Geubels, Barbara, Gregory, Ellen, Salazar, Ivana P., Herrando, Ignacio, Hill, J., Huq, Z., Jacquinot, Frederique, Jakobsen, Anders, Jensen, Lars Henrik, Jones, D., Keshvari, Amir, Ketelaers, Stijn H.J., Khan, U., Kushwaha, R., Kordnejad, Shahrzad, Leitner, Kurt, Madoff, Robert, Malcomson, Lee, Martling, Anna, Fechner, Katja, Matzel, Klaus E., Mazzarisi, Claudia, Meershoek, Elma, Melenhorst, Jarno, Nouritaromlou, Mohammed, Paolo, Goffredo, Pennings, Alexander, Murad-Regadas, Sthela M., Pandini, Rafael, Peeters, Koen C.M.J., Rawat, S., Richards, D., Rosa, Isadora, Rossi, Gustavo, Rutten, Harm J.T., Sanchez Loria, Fernando, Santiago, Ines, Siddiqui, K.H., Solkar, M.H., Sun Myint, Arthur, Telford, K., Tang, J., Temmink, Sofieke, Tokmak, Handan, Vaccaro, Carlos A., Ward, S., Wolthuis, Albert M., Wytze, Lameris, Yu, Jiehai, and Zhang, Zhen

Published
2024
Full Text
View/download PDF

2. A multi-centre randomized controlled trial investigating Consolidation Chemotherapy with and without oxaliplatin in distal rectal cancer and Watch & Wait

Author

Angelita Habr-Gama, Guilherme Pagin São Julião, Cinthia D. Ortega, Bruna Borba Vailati, Sergio Araujo, Thiago Jorge, Jorge Sabbaga, Gustavo L. Rossi, Renata D’Alpino, Fabio Roberto Kater, Patricia Bailão Aguilar, Adrian Mattacheo, Rodrigo Oliva Perez, and Latin American Rectal Cancer Consortium (LARCC)

Subjects
Rectal Cancer, Complete Clinical Response, Watch and Wait, Total neoadjuvant treatment, Consolidation chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Neoadjuvant chemoradiation(nCRT) has been considered the preferred initial treatment strategy for distal rectal cancer. Advantages of this approach include improved local control after radical surgery but also the opportunity for organ preserving strategies (Watch and Wait-WW). Consolidation chemotherapy(cCT) regimens using fluoropyrimidine-based with or without oxalipatin following nCRT have demonstrated to increase complete response and organ preservation rates among these patients. However, the benefit of adding oxaliplatin to cCT compared to fluoropirimidine alone regimens in terms of primary tumor response remains unclear. Since oxalipatin-treatment may be associated with considerable toxicity, it becomes imperative to understand the benefit of its incorporation into standard cCT regimens in terms of primary tumor response. The aim of the present trial is to compare the outcomes of 2 different cCT regimens following nCRT (fluoropyrimidine-alone versus fluoropyrimidine + oxaliplatin) for patients with distal rectal cancer. Methods In this multi-centre study, patients with magnetic resonance-defined distal rectal tumors will be randomized on a 1:1 ratio to receive long-course chemoradiation (54 Gy) followed by cCT with fluoropyrimidine alone versus fluoropyrimidine + oxaliplatin. Magnetic resonance(MR) will be analyzed centrally prior to patient inclusion and randomization. mrT2-3N0-1 tumor located no more than 1 cm above the anorectal ring determined by sagittal views on MR will be eligible for the study. Tumor response will be assessed after 12 weeks from radiotherapy(RT) completion. Patients with clinical complete response (clinical, endoscopic and radiological) may be enrolled in an organ-preservation program(WW). The primary endpoint of this trial is decision to organ-preservation surveillance (WW) at 18 weeks from RT completion. Secondary endpoints are 3-year surgery-free survival, TME-free survival, distant metastases-free survival, local regrowth-free survival and colostomy-free survival. Discussion Long-course nCRT with cCT is associated with improved complete response rates and may be a very attractive alternative to increase the chances for organ-preservation strategies. Fluoropyrimidine-based cCT with or without oxaliplatin has never been investigated in the setting of a randomized trial to compare clinical response rates and the possibility of organ-preservation. The outcomes of this study may significantly impact clinical practice of patients with distal rectal cancer interested in organ-preservation. Trial registration www.clinicaltrials.gov NCT05000697; registered on August 11th, 2021.

Published
2023
Full Text
View/download PDF

6. Rectal Cancer: Watch and Wait

Author

Habr-Gama, Angelita, São Julião, Guilherme Pagin, Vailati, Bruna Borba, Perez, Rodrigo Oliva, Steele, Scott R., editor, Maykel, Justin A., editor, and Wexner, Steven D., editor

Published
2020
Full Text
View/download PDF

8. Organ-preservation in rectal cancer: What is at risk when offering watch and wait for a clinical complete response? Data from 2 international registries in rectal cancer.

Author

Fernandez, Laura Melina, primary, São Julião, Guilherme Pagin, additional, Vailati, Bruna Borba, additional, Santacruz, Carlos Cerdan, additional, Renehan, Andrew, additional, Beets, Geerard, additional, Habr-Gama, Angelita, additional, Azevedo, José Moreira, additional, Parvaiz, Amjad, additional, and Perez, Rodrigo O., additional

Published
2024
Full Text
View/download PDF

13. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis

Author

Chadi, Sami A, Malcomson, Lee, Ensor, Joie, Riley, Richard D, Vaccaro, Carlos A, Rossi, Gustavo L, Daniels, Ian R, Smart, Neil J, Osborne, Melanie E, Beets, Geerard L, Maas, Monique, Bitterman, Danielle S, Du, Kevin, Gollins, Simon, Sun Myint, Arthur, Smith, Fraser M, Saunders, Mark P, Scott, Nigel, O'Dwyer, Sarah T, de Castro Araujo, Rodrigo Otavio, Valadao, Marcus, Lopes, Alberto, Hsiao, Cheng-Wen, Lai, Chien-Liang, Smith, Radhika K, Paulson, Emily Carter, Appelt, Ane, Jakobsen, Anders, Wexner, Steven D, Habr-Gama, Angelita, Sao Julião, Guilherme, Perez, Rodrigo O, and Renehan, Andrew G

Published
2018
Full Text
View/download PDF

15. Local Regrowth and the Risk of Distant Metastases Among Patients Undergoing Watch-and-Wait for Rectal Cancer: What Is the Best Control Group? Multicenter Retrospective Study

Author

São Julião, Guilherme Pagin, primary, Fernández, Laura M., additional, Vailati, Bruna Borba, additional, Habr-Gama, Angelita, additional, Azevedo, José M., additional, Santiago, Inês A., additional, Parés, Oriol, additional, Parvaiz, Amjad, additional, Vendrely, Véronique, additional, Rullier, Anne, additional, Rullier, Eric, additional, Denost, Quentin, additional, and Perez, Rodrigo Oliva, additional

Published
2023
Full Text
View/download PDF

16. New Strategies in Rectal Cancer

Author

São Julião, Guilherme Pagin, Habr-Gama, Angelita, Vailati, Bruna Borba, Araujo, Sergio Eduardo Alonso, Fernandez, Laura Melina, and Perez, Rodrigo Oliva

Published
2017
Full Text
View/download PDF

17. The Contribution of 700,000 ORF Sequence Tags to the Definition of the Human Transcriptome

Author

Camargo, Anamaria A., Dias-Neto, Emmanuel, Simão, Daniel F., Migotto, Italo A., Costa, Fernando F., Nagai, Maria Aparecida, Verjovski-Almeida, Sergio, Zago, Marco A., Carrer, Helaine, Espreafico, Enilza M., Habr-Gama, Angelita, Giannella-Neto, Daniel, Goldman, Gustavo H., Gruber, Arthur, Hackel, Christine, Kimura, Edna T., Nóbrega, Marina P., Paçó-Larson, Maria Luisa, Pereira, Gonçalo G., Pesquero, João Bosco, Rodrigues, Vanderlei, Rogatto, Silvia R., Sogayar, Mari C., Tajara, Eloiza H., Valentini, Sandro R., Alberto, Fernando L., Aneas, Ivy, de Assis, Angela M., Bengtso, Mário Henrique, Bergamo, Nadia Aparecida, Bombonato, Vanessa, Canevari, Renata A., Carraro, Dirce M., Cerutti, Janete M., Curcio, Cyntia, Furuzawa, Gilberto K., Gushiken, Tsieko, Ho, Paulo L., Kimura, Elza, Krieger, José E., Majumder, Paromita, Marins, Mozart, Marques, Everaldo R., Melo, Monica, Mestriner, Carlos Alberto, Miracca, Elisabete C., Miranda, Daniela C., Nóbrega, Francisco G., Pessoa, Luciana G., Prevedel, Aline C., Rahal, Paula, Rainho, Claudia A., Ribeiro, Marcelo L., da Rós, Nancy, de Sá, Renata G., Sales, Magaly M., da Silva, Aline M., da Silva, Neusa P., Silva, Wilson A., da Silveira, Rosana A., Sousa, Josane F., Stecconi, Daniella, Tsukumo, Fernando, Valente, Valéria, Soares, Fernando, Moreira, Eloisa S., Nunes, Diana N., Correa, Ricardo G., Zalcberg, Heloisa, Carvalho, Alex F., Brentani, Ricardo R., and de Souza, Sandro J.

Published
2001

19. Identification of Human Chromosome 22 Transcribed Sequences with ORF Expressed Sequence Tags

Author

De Souza, Sandro J., Camargo, Anamaria A., Costa, Fernando F., Nagai, Maria Aparecida, Verjovski-Almeida, Sergio, Zago, Marco A., Carrer, Helaine, Espreafico, Enilza M., Habr-Gama, Angelita, Giannella-Neto, Daniel, Goldman, Gustavo H., Gruber, Arthur, Hackel, Christine, Kimura, Edna T., Nobrega, Marina P., Paco-Larson, Maria Luisa, Pereira, Goncalo G., Pesquero, Joao Bosco, Rodrigues, Vanderlei, Rogatto, Silvia R., Sogayar, Mari C., Tajara, Eloiza H., Valentini, Sandro R., Acencio, Marcio, Alberto, Fernando L., Aneas, Ivy, Bengtson, Mario Henrique, Carraro, Dirce M., Carvalho, Alex F., Carvalho, Lucia Helena, Cerutti, Janete M., Curcio, Cyntia, Gushiken, Tsieko, Ho, Paulo L., Kimura, Elza, Maia, Gustavo, Majumder, Paromita, Marins, Mozart, Matsukuma, Adriana, Mestriner, Carlos Alberto, Miracca, Elisabete C., Miranda, Daniela C., Nobrega, Francisco G., Pessoa, Luciana Gilbert, Rahal, Paula, Rainho, Claudia A., De Sa, Renata G., Sales, Magaly M., Da Silva, Neusa P., Silva, Tereza C., da Silva,, Wilson, Simao, Daniel F., Sousa, Josane F., Stecconi, Daniella, Tsukumo, Fernando, Valente, Valeria, Zalcberg, Heloisa, Brentani, Ricardo R., and Dias-Neto, Emmanuel

Published
2000

26. Local Excision of Rectal Cancer

Author

Habr-Gama, Angelita, Figueiredo, Marleny Novaes, Fernandez, Laura Melina, São Julião, Guilherme Pagin, Perez, Rodrigo Oliva, Longo, Walter E., editor, Reddy, Vikram, editor, and Audisio, Riccardo A., editor

Published
2015
Full Text
View/download PDF

30. Watch and Wait Approach for Rectal Cancer

Author

Cerdan-Santacruz, Carlos, primary, São Julião, Guilherme Pagin, additional, Vailati, Bruna Borba, additional, Corbi, Leonardo, additional, Habr-Gama, Angelita, additional, and Perez, Rodrigo Oliva, additional

Published
2023
Full Text
View/download PDF

31. Supplementary Figures from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

El Sissy, Carine, primary, Kirilovsky, Amos, primary, Van den Eynde, Marc, primary, Muşină, Ana-Maria, primary, Anitei, Maria-Gabriela, primary, Romero, Alfredo, primary, Marliot, Florence, primary, Junca, Audelaure, primary, Doyen, Jérôme, primary, Mlecnik, Bernhard, primary, Haicheur, Nacilla, primary, Fredriksen, Tessa, primary, Lagorce, Christine, primary, Jouret-Mourin, Anne, primary, Leonard, Daniel, primary, Bibeau, Frédéric, primary, Iseas, Soledad, primary, Roca, Enrique L., primary, Cabanne, Ana M., primary, Vaccaro, Carlos A., primary, Santino, Juan P., primary, Huertas, Eduardo, primary, Tougeron, David, primary, Carvalho, Carlos, primary, Figueiredo, Nuno, primary, Perez, Rodrigo O., primary, Habr-Gama, Angelita, primary, Scripcariu, Viorel, primary, Gerard, Jean-Pierre, primary, Galon, Jérôme, primary, Zeitoun, Guy, primary, and Pagès, Franck, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Tables from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

El Sissy, Carine, primary, Kirilovsky, Amos, primary, Van den Eynde, Marc, primary, Muşină, Ana-Maria, primary, Anitei, Maria-Gabriela, primary, Romero, Alfredo, primary, Marliot, Florence, primary, Junca, Audelaure, primary, Doyen, Jérôme, primary, Mlecnik, Bernhard, primary, Haicheur, Nacilla, primary, Fredriksen, Tessa, primary, Lagorce, Christine, primary, Jouret-Mourin, Anne, primary, Leonard, Daniel, primary, Bibeau, Frédéric, primary, Iseas, Soledad, primary, Roca, Enrique L., primary, Cabanne, Ana M., primary, Vaccaro, Carlos A., primary, Santino, Juan P., primary, Huertas, Eduardo, primary, Tougeron, David, primary, Carvalho, Carlos, primary, Figueiredo, Nuno, primary, Perez, Rodrigo O., primary, Habr-Gama, Angelita, primary, Scripcariu, Viorel, primary, Gerard, Jean-Pierre, primary, Galon, Jérôme, primary, Zeitoun, Guy, primary, and Pagès, Franck, primary

Published
2023
Full Text
View/download PDF

33. The Risk of Distant Metastases in Patients With Clinical Complete Response Managed by Watch and Wait After Neoadjuvant Therapy for Rectal Cancer: The Influence of Local Regrowth in the International Watch and Wait Database

Author

Fernandez, Laura M, São Julião, Guilherme P, Renehan, Andrew G, Beets, Geerard L, Papoila, Ana L, Vailati, Bruna B, Bahadoer, Renu R, Kranenbarg, Elma Meershoek-Klein, Roodvoets, Annet G H, Figueiredo, Nuno L, Van De Velde, Cornelis J H, Habr-Gama, Angelita, Perez, Rodrigo O, International Watch & Wait Database (IWWD) Consortium, Fernandez, Laura M, São Julião, Guilherme P, Renehan, Andrew G, Beets, Geerard L, Papoila, Ana L, Vailati, Bruna B, Bahadoer, Renu R, Kranenbarg, Elma Meershoek-Klein, Roodvoets, Annet G H, Figueiredo, Nuno L, Van De Velde, Cornelis J H, Habr-Gama, Angelita, Perez, Rodrigo O, and International Watch & Wait Database (IWWD) Consortium

Abstract

BACKGROUND: Nearly 30% of patients with rectal cancer develop local regrowth after initial clinical complete response managed by watch and wait. These patients might be at higher risk for distant metastases.OBJECTIVE: This study aimed to investigate risk factors for distant metastases using time-dependent analyses.DESIGN: Data from an international watch and wait database were retrospectively reviewed. Cox regression analysis was used to determine risk factors for worse distant metastases-free survival. Conditional survival modeling was used to investigate the impact of risk factors on the development of distant metastases.SETTING: Retrospective, multicenter database.PATIENTS: A total of 793 patients (47 institutions) with rectal cancer and clinical complete response to neoadjuvant treatment from the International Watch & Wait Database were included.MAIN OUTCOME MEASURES: Distant metastases-free survival.RESULTS: Of the 793 patients managed with watch and wait (median follow-up 55.2 mo)' 85 patients (10.7%) had distant metastases. Fifty-one of 85 patients (60%) had local regrowth at any time. Local regrowth was an independent factor associated with worse distant metastases-free survival in the multivariable model. Using conditional estimates, patients with local regrowth without distant metastases for 5 years (from decision to watch and wait) remained at higher risk for development of distant metastases for 1 subsequent year compared to patients without local regrowth (5-year conditional distant metastases-free survival 94.9% vs 98.4%).LIMITATIONS: Lack of information on adjuvant chemotherapy, salvage surgery for local regrowth, and heterogeneity of individual surveillance/follow-up strategies used may have affected results.CONCLUSIONS: In patients with clinical complete response managed by watch and wait, development of local regrowth at any time is a risk factor for distant metastases. The risk of dist

Published
2023

34. The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer—The Impact in Intratumoral Heterogeneity

Author

Fabiana Bettoni, Cibele Masotti, Bruna R. Corrêa, Elisa Donnard, Filipe F. dos Santos, Guilherme P. São Julião, Bruna B. Vailati, Angelita Habr-Gama, Pedro A. F. Galante, Rodrigo O. Perez, and Anamaria A. Camargo

Subjects
neoadjuvant therapy, rectal cancer, intratumoral heterogeneity, clonal evolution, therapy resistance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Purpose: Intratumoral genetic heterogeneity (ITGH) is a common feature of solid tumors. However, little is known about the effect of neoadjuvant chemoradiation (nCRT) in ITGH of rectal tumors that exhibit poor response to nCRT. Here, we examined the impact of nCRT in the mutational profile and ITGH of rectal tumors and its adjacent irradiated normal mucosa in the setting of incomplete response to nCRT.Methods and Materials: To evaluate ITGH in rectal tumors, we analyzed whole-exome sequencing (WES) data from 79 tumors obtained from The Cancer Genome Atlas (TCGA). We also compared matched peripheral blood cells, irradiated normal rectal mucosa and pre and post-treatment tumor samples (PRE-T and POS-T) from one individual to examine the iatrogenic effects of nCRT. Finally, we performed WES of 7 PRE-T/POST-T matched samples to examine how nCRT affects ITGH. ITGH was assessed by quantifying subclonal mutations within individual tumors using the Mutant-Allele Tumor Heterogeneity score (MATH score).Results: Rectal tumors exhibit remarkable ITGH that is ultimately associated with disease stage (MATH score stage I/II 35.54 vs. stage III/IV 44.39, p = 0.047) and lymph node metastasis (MATH score N0 35.87 vs. N+ 45.79, p = 0.026). We also showed that nCRT does not seem to introduce detectable somatic mutations in the irradiated mucosa. Comparison of PRE-T and POST-T matched samples revealed a significant increase in ITGH in 5 out 7 patients and MATH scores were significantly higher after nCRT (median 41.7 vs. 28.8, p = 0.04). Finally, we were able to identify a subset of “enriched mutations” with significant changes in MAFs between PRE-T and POST-T samples. These “enriched mutations” were significantly more frequent in POST-T compared to PRE-T samples (92.9% vs. 7.1% p < 0.00001) and include mutations in genes associated with genetic instability and drug resistance in colorectal cancer, indicating the expansion of tumor cell subpopulations more prone to resist to nCRT.Conclusions: nCRT increases ITGH and may result in the expansion of resistant tumor cell populations in residual tumors. The risk of introducing relevant somatic mutations in the adjacent mucosa is minimal but non-responsive tumors may have potentially worse biological behavior when compared to their untreated counterparts. This was an exploratory study, and due to the limited number of samples analyzed, our results need to be validated in larger cohorts.

Published
2019
Full Text
View/download PDF

35. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer

Author

Lutz, Manfred P., Zalcberg, John R., Glynne-Jones, Rob, Ruers, Theo, Ducreux, Michel, Arnold, Dirk, Aust, Daniela, Brown, Gina, Bujko, Krzysztof, Cunningham, Christopher, Evrard, Serge, Folprecht, Gunnar, Gerard, Jean-Pierre, Habr-Gama, Angelita, Haustermans, Karin, Holm, Torbjörn, Kuhlmann, Koert F., Lordick, Florian, Mentha, Gilles, Moehler, Markus, Nagtegaal, Iris D., Pigazzi, Alessio, Pucciarelli, Salvatore, Roth, Arnaud, Rutten, Harm, Schmoll, Hans-Joachim, Sorbye, Halfdan, Van Cutsem, Eric, Weitz, Jürgen, and Otto, Florian

Published
2016
Full Text
View/download PDF

36. Data from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

Franck Pagès, Guy Zeitoun, Jérôme Galon, Jean-Pierre Gerard, Viorel Scripcariu, Angelita Habr-Gama, Rodrigo O. Perez, Nuno Figueiredo, Carlos Carvalho, David Tougeron, Eduardo Huertas, Juan P. Santino, Carlos A. Vaccaro, Ana M. Cabanne, Enrique L. Roca, Soledad Iseas, Frédéric Bibeau, Daniel Leonard, Anne Jouret-Mourin, Christine Lagorce, Tessa Fredriksen, Nacilla Haicheur, Bernhard Mlecnik, Jérôme Doyen, Audelaure Junca, Florence Marliot, Alfredo Romero, Maria-Gabriela Anitei, Ana-Maria Muşină, Marc Van den Eynde, Amos Kirilovsky, and Carine El Sissy

Abstract

Purpose:No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is currently available. We assessed in LARC whether a diagnostic biopsy-adapted immunoscore (ISB) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy (“Watch-and-Wait”).Experimental Design:Biopsies from two independent cohorts (n1 = 131, n2 = 118) of patients with LARC treated with nT followed by radical surgery were immunostained for CD3+ and CD8+ T cells and quantified by digital pathology to determine ISB. The expression of immune-related genes post-nT was investigated (n = 64 patients). Results were correlated with response to nT and disease-free survival (DFS). The ISB prognostic performance was further assessed in a multicentric cohort (n = 73 patients) treated by Watch-and-Wait.Results:ISB positively correlated with the degree of histologic response (P < 0.001) and gene expression levels for Th1 orientation and cytotoxic immune response, post-nT (P = 0.006). ISB high identified patients at lower risk of relapse or death compared with ISB low [HR, 0.21; 95% confidence interval (CI), 0.06–0.78; P = 0.009]. Prognostic performance of ISB for DFS was confirmed in a validation cohort. ISB was an independent parameter, more informative than pre- (P < 0.001) and post-nT (P < 0.05) imaging to predict DFS. ISB combined with imaging post-nT discriminated very good responders that could benefit from organ preservation strategy. In the “Watch-and-Wait” cohort (n = 73), no relapse was observed in patients with ISB high (23.3%).Conclusions:ISB predicts response to nT and survival in patients with LARC treated by surgery. Its usefulness in the selection of patients eligible for a Watch-and-Wait strategy is strongly suggested.

Published
2023

37. Supplementary Figures from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

Franck Pagès, Guy Zeitoun, Jérôme Galon, Jean-Pierre Gerard, Viorel Scripcariu, Angelita Habr-Gama, Rodrigo O. Perez, Nuno Figueiredo, Carlos Carvalho, David Tougeron, Eduardo Huertas, Juan P. Santino, Carlos A. Vaccaro, Ana M. Cabanne, Enrique L. Roca, Soledad Iseas, Frédéric Bibeau, Daniel Leonard, Anne Jouret-Mourin, Christine Lagorce, Tessa Fredriksen, Nacilla Haicheur, Bernhard Mlecnik, Jérôme Doyen, Audelaure Junca, Florence Marliot, Alfredo Romero, Maria-Gabriela Anitei, Ana-Maria Muşină, Marc Van den Eynde, Amos Kirilovsky, and Carine El Sissy

Abstract

Supplementary Figures

Published
2023

38. Supplementary Tables from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Author

Franck Pagès, Guy Zeitoun, Jérôme Galon, Jean-Pierre Gerard, Viorel Scripcariu, Angelita Habr-Gama, Rodrigo O. Perez, Nuno Figueiredo, Carlos Carvalho, David Tougeron, Eduardo Huertas, Juan P. Santino, Carlos A. Vaccaro, Ana M. Cabanne, Enrique L. Roca, Soledad Iseas, Frédéric Bibeau, Daniel Leonard, Anne Jouret-Mourin, Christine Lagorce, Tessa Fredriksen, Nacilla Haicheur, Bernhard Mlecnik, Jérôme Doyen, Audelaure Junca, Florence Marliot, Alfredo Romero, Maria-Gabriela Anitei, Ana-Maria Muşină, Marc Van den Eynde, Amos Kirilovsky, and Carine El Sissy

Abstract

Supplementary Tables

Published
2023

42. Anatomy and Embryology of the Colon, Rectum, and Anus

Author

Jorge, Jose Marcio Neves, Habr-Gama, Angelita, Beck, David E., editor, Wexner, Steven D., editor, Hull, Tracy L., editor, Roberts, Patricia L., editor, Saclarides, Theodore J., editor, Senagore, Anthony J., editor, Stamos, Michael J., editor, and Steele, Scott R., editor

Published
2014
Full Text
View/download PDF

44. Intestinal Mucosa-Associated Microflora in Ulcerative Colitis Patients Before and After Restorative Proctocolectomy with an Ileoanal Pouch

Author

Almeida, Maristela, Kiss, Desidério, Zilberstein, Bruno, Quintanilha, Alina, Teixeira, Magaly, and Habr-Gama, Angelita

Abstract

Abstract: Purpose: This study was designed to identify the mucosa-associated microflora in patients with severe ulcerative colitis before and after restorative proctocolectomy with ileoanal pouch construction in comparison with historic controls. Methods: Ten patients with a diagnosis of ulcerative colitis were evaluated. Mucus was collected during colonoscopy from all segments of the colon and terminal ileum before surgery, and from the ileal pouch two and eight months after ileostomy closure. The prevalence and mean concentration of the mucosa-associated microflora were compared over time and with historic controls. Results: Veillonella sp was the most prevalent bacterium in patients and controls. Klebsiella sp was significantly more prevalent in the ileum of controls, was not found in patients with ulcerative colitis, and after proctocolectomy returned to values found in controls. Some bacteria such as Enterobacter sp, Staphylococcus sp (coag-), Bacteroides sp (npg), Lactobacillus sp, and Veillonella sp had higher mean concentrations in the ileal pouch of patients after surgery than in controls. Conclusion: No bacterium was identified that could be exclusively responsible for the maintenance of the inflammatory process. The mucosa-associated microflora of patients with ulcerative colitis underwent significant changes after proctocolectomy with ileal pouch construction and returned to almost normal values for some bacteria.

Published
2024
Full Text
View/download PDF

49. Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer

Author

Lopes-Ramos, Camila, Koyama, Fernanda C., Habr-Gama, Angelita, Salim, Anna Christina M., Bettoni, Fabiana, Asprino, Paula F., França, Gustavo S., Gama-Rodrigues, Joaquim, Parmigiani, Raphael B., Perez, Rodrigo O., Galante, Pedro A.F., and Camargo, Anamaria A.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results